Anileridine

Anileridine2DCSD.svg

Synthetic opioid analgesic

Engineered Monoclonal Antibodies

Diagram of engineered monoclonal antibodies

Engineered monoclonal antibodies are a class of biological therapies that are designed to target specific antigens on the surface of cells. These antibodies are produced using recombinant DNA technologies and are used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

Structure and Function

Monoclonal antibodies are composed of two identical heavy chains and two identical light chains, forming a Y-shaped molecule. The tips of the "Y" contain the antigen-binding sites, which are highly specific to the target antigen. This specificity allows monoclonal antibodies to bind to their target with high affinity, blocking or modulating the function of the antigen.

Types of Engineered Monoclonal Antibodies

There are several types of engineered monoclonal antibodies, each designed for specific therapeutic purposes:

• Chimeric antibodies: These antibodies are composed of murine (mouse) variable regions and human constant regions. They are less immunogenic than fully murine antibodies.

• Humanized antibodies: These antibodies are mostly human, with only the antigen-binding sites derived from murine sources. This reduces the risk of immune reactions.

• Fully human antibodies: These are entirely human in origin, produced using transgenic mice or phage display technologies.

• Bispecific antibodies: These antibodies are engineered to bind two different antigens simultaneously, offering unique therapeutic mechanisms.

Applications in Medicine

Engineered monoclonal antibodies have revolutionized the treatment of many diseases:

• Cancer therapy: Monoclonal antibodies can target specific tumor antigens, leading to direct tumor cell killing or recruitment of immune cells to attack the tumor.

• Autoimmune diseases: By targeting specific components of the immune system, monoclonal antibodies can reduce inflammation and tissue damage in diseases such as rheumatoid arthritis and multiple sclerosis.

• Infectious diseases: Monoclonal antibodies can neutralize pathogens or their toxins, providing passive immunity or enhancing the host's immune response.

Production

The production of engineered monoclonal antibodies involves several steps:

1. Antigen identification: The target antigen is identified and characterized. 2. Hybridoma technology: B cells from immunized animals are fused with myeloma cells to create hybridomas that produce the desired antibody. 3. Recombinant DNA technology: Genes encoding the antibody are cloned and expressed in suitable host cells, such as Chinese hamster ovary cells. 4. Purification and formulation: The antibodies are purified and formulated for clinical use.

Challenges and Future Directions

While engineered monoclonal antibodies have shown great promise, there are challenges such as high production costs, potential for immune reactions, and the development of resistance. Ongoing research aims to improve antibody design, reduce immunogenicity, and enhance therapeutic efficacy.

Related Pages

• Monoclonal antibody therapy
• Biopharmaceutical
• Immunotherapy
• Hybridoma technology

Anileridine is a synthetic opioid analgesic that is structurally related to pethidine (meperidine). It was developed in the 1950s by the pharmaceutical company Merck & Co. as a potential alternative to pethidine with a better side effect profile.

Pharmacology

Anileridine works by binding to the opioid receptors in the central nervous system, which leads to the inhibition of pain signals. It is primarily used for the management of moderate to severe pain. The drug has a similar mechanism of action to other opioids, such as morphine and fentanyl, but with some differences in its pharmacokinetic properties.

Medical Uses

Anileridine is indicated for the relief of moderate to severe pain. It is often used in a hospital setting for postoperative pain management and in patients who require continuous pain relief. The drug can be administered orally or via intravenous injection.

Side Effects

Common side effects of anileridine include nausea, vomiting, dizziness, and constipation. Like other opioids, it has the potential for abuse and dependence. Overdose can lead to severe respiratory depression and death.

Legal Status

Anileridine is classified as a controlled substance in many countries due to its potential for abuse and dependence. In the United States, it is listed as a Schedule II controlled substance under the Controlled Substances Act.

History

Anileridine was first synthesized in the 1950s by Merck & Co. It was introduced as a potential alternative to pethidine, with the aim of providing effective pain relief with fewer side effects. However, its use has declined over the years with the development of newer analgesics.

See Also

• Opioid
• Analgesic
• Pethidine
• Morphine
• Fentanyl

References

This article is a stub related to medicine. You can help WikiMD by expanding it!